NO326035B1 - Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse. - Google Patents
Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse. Download PDFInfo
- Publication number
- NO326035B1 NO326035B1 NO20012818A NO20012818A NO326035B1 NO 326035 B1 NO326035 B1 NO 326035B1 NO 20012818 A NO20012818 A NO 20012818A NO 20012818 A NO20012818 A NO 20012818A NO 326035 B1 NO326035 B1 NO 326035B1
- Authority
- NO
- Norway
- Prior art keywords
- cell lines
- immunotherapeutic agent
- prostate cancer
- allogeneic
- cells
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title claims abstract description 29
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 24
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 229960005486 vaccine Drugs 0.000 title claims abstract description 14
- 239000002955 immunomodulating agent Substances 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title claims description 21
- 239000003795 chemical substances by application Substances 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims description 92
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 239000002671 adjuvant Substances 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 230000001394 metastastic effect Effects 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 7
- 208000023958 prostate neoplasm Diseases 0.000 claims description 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000012646 vaccine adjuvant Substances 0.000 claims description 6
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 6
- 239000002577 cryoprotective agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000588832 Bordetella pertussis Species 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000000704 Interleukin-7 Human genes 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 239000008150 cryoprotective solution Substances 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 229940117681 interleukin-12 Drugs 0.000 claims description 4
- 229940028885 interleukin-4 Drugs 0.000 claims description 4
- 229940100994 interleukin-7 Drugs 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 241000187644 Mycobacterium vaccae Species 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 claims description 2
- 230000016784 immunoglobulin production Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 18
- 238000009169 immunotherapy Methods 0.000 abstract description 13
- 238000001574 biopsy Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 208000010658 metastatic prostate carcinoma Diseases 0.000 abstract description 3
- 230000010076 replication Effects 0.000 abstract description 3
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000013459 approach Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 239000006166 lysate Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000003902 lesion Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 5
- 229940030156 cell vaccine Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000005267 prostate cell Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710164309 56 kDa type-specific antigen Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 102100034763 Peroxiredoxin-2 Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 238000001709 templated self-assembly Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229950004398 broxuridine Drugs 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000064 prostate epithelial cell Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005521 allovectin-7 Drugs 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940038872 cell-based cancer vaccine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 108010032337 diaminobenzidine peroxidase Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000004014 triple-axis neutron scattering Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827103.4A GB9827103D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| PCT/GB1999/004135 WO2000033870A2 (fr) | 1998-12-10 | 1999-12-09 | Nouveaux traitements contre le cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012818D0 NO20012818D0 (no) | 2001-06-07 |
| NO20012818L NO20012818L (no) | 2001-06-07 |
| NO326035B1 true NO326035B1 (no) | 2008-09-01 |
Family
ID=10843925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012818A NO326035B1 (no) | 1998-12-10 | 2001-06-07 | Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6699483B1 (fr) |
| EP (1) | EP1137434B1 (fr) |
| JP (1) | JP4607330B2 (fr) |
| KR (1) | KR100612552B1 (fr) |
| AT (1) | ATE412425T1 (fr) |
| AU (1) | AU777969B2 (fr) |
| CA (1) | CA2354046C (fr) |
| CZ (1) | CZ20012033A3 (fr) |
| DE (1) | DE69939837D1 (fr) |
| ES (1) | ES2315024T3 (fr) |
| GB (1) | GB9827103D0 (fr) |
| HU (1) | HUP0104857A3 (fr) |
| IL (2) | IL143295A0 (fr) |
| MX (1) | MXPA01005815A (fr) |
| NO (1) | NO326035B1 (fr) |
| NZ (1) | NZ512005A (fr) |
| PL (1) | PL348829A1 (fr) |
| WO (1) | WO2000033870A2 (fr) |
| ZA (1) | ZA200104163B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2404388C (fr) * | 2000-04-01 | 2010-06-15 | Onyvax Limited | Nouvelles lignees cellulaires prostatiques |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| CA2950109C (fr) | 2000-10-27 | 2019-02-19 | John W. Hadden | Immunotherapie vaccinale pour patients immunodeprimes |
| CN1774255A (zh) * | 2002-02-22 | 2006-05-17 | 英特拉舍尔资源有限责任公司 | 无菌免疫原性非－致瘤性肿瘤细胞组合物和方法 |
| US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
| US20050019336A1 (en) * | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| MXPA06002159A (es) * | 2003-08-26 | 2006-05-22 | Becton Dickinson Co | Metodos para la administracion intradermica de agentes terapeuticos. |
| EP2591786B1 (fr) | 2003-10-16 | 2017-04-12 | Cancure Limited | Compositions immunomodulatrices et leurs utilisations |
| US8257715B1 (en) | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
| EP2446897A1 (fr) | 2005-01-06 | 2012-05-02 | Novo Nordisk A/S | Traitements de combinaison anti-KIR et procédés |
| US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
| US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| GB0601598D0 (en) * | 2006-01-26 | 2006-03-08 | Stathopoulos Apostolos | Method |
| US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| US20110250218A1 (en) | 2008-10-29 | 2011-10-13 | Fong Lawrence H | Disease-Associated Antigens and Methods of Use Thereof |
| WO2010132867A1 (fr) | 2009-05-15 | 2010-11-18 | Irx Therapeutics, Inc. | Immunothérapie par vaccin |
| US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
| US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
| US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| CN105850981B (zh) * | 2016-04-29 | 2018-07-20 | 绍兴市人民医院 | 冻存肿瘤组织的方法 |
| CN105850982B (zh) * | 2016-04-29 | 2018-08-17 | 绍兴市人民医院 | 一种新型组织冻存液 |
| CN114729324A (zh) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | 永生化干细胞株的制备方法及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| DE69627527T2 (de) * | 1995-12-28 | 2004-03-04 | The Johns Hopkins University School Of Medicine | Allogene parakrine cytokine tumor impfstoffe |
| CA2245099C (fr) | 1996-02-02 | 2007-01-09 | Suzanne L. Topalian | Lignees de cellules epitheliales immortalisees provenant de prostate d'origine humaine, clones correspondants et leurs applications s'agissant de recherche et de therapie du cancer de la prostate |
| JP2002529707A (ja) * | 1998-11-03 | 2002-09-10 | セル ジェネシス インコーポレイテッド | 癌関連抗原およびそれらの同定の方法 |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827103.4A patent/GB9827103D0/en not_active Ceased
-
1999
- 1999-12-09 PL PL99348829A patent/PL348829A1/xx unknown
- 1999-12-09 WO PCT/GB1999/004135 patent/WO2000033870A2/fr active IP Right Grant
- 1999-12-09 CA CA2354046A patent/CA2354046C/fr not_active Expired - Fee Related
- 1999-12-09 CZ CZ20012033A patent/CZ20012033A3/cs unknown
- 1999-12-09 HU HU0104857A patent/HUP0104857A3/hu unknown
- 1999-12-09 NZ NZ512005A patent/NZ512005A/xx unknown
- 1999-12-09 DE DE69939837T patent/DE69939837D1/de not_active Expired - Lifetime
- 1999-12-09 EP EP99959548A patent/EP1137434B1/fr not_active Expired - Lifetime
- 1999-12-09 KR KR1020017007095A patent/KR100612552B1/ko not_active IP Right Cessation
- 1999-12-09 MX MXPA01005815A patent/MXPA01005815A/es active IP Right Grant
- 1999-12-09 AU AU16687/00A patent/AU777969B2/en not_active Ceased
- 1999-12-09 JP JP2000586360A patent/JP4607330B2/ja not_active Expired - Fee Related
- 1999-12-09 US US09/857,690 patent/US6699483B1/en not_active Expired - Lifetime
- 1999-12-09 IL IL14329599A patent/IL143295A0/xx active IP Right Grant
- 1999-12-09 AT AT99959548T patent/ATE412425T1/de not_active IP Right Cessation
- 1999-12-09 ES ES99959548T patent/ES2315024T3/es not_active Expired - Lifetime
-
2001
- 2001-05-22 IL IL143295A patent/IL143295A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104163A patent/ZA200104163B/en unknown
- 2001-06-07 NO NO20012818A patent/NO326035B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0104857A3 (en) | 2004-04-28 |
| GB9827103D0 (en) | 1999-02-03 |
| ATE412425T1 (de) | 2008-11-15 |
| CA2354046C (fr) | 2011-02-15 |
| CA2354046A1 (fr) | 2000-06-15 |
| NO20012818D0 (no) | 2001-06-07 |
| NO20012818L (no) | 2001-06-07 |
| IL143295A0 (en) | 2002-04-21 |
| DE69939837D1 (de) | 2008-12-11 |
| JP4607330B2 (ja) | 2011-01-05 |
| AU1668700A (en) | 2000-06-26 |
| PL348829A1 (en) | 2002-06-17 |
| EP1137434A2 (fr) | 2001-10-04 |
| KR100612552B1 (ko) | 2006-08-11 |
| ES2315024T3 (es) | 2009-03-16 |
| EP1137434B1 (fr) | 2008-10-29 |
| KR20010090873A (ko) | 2001-10-19 |
| WO2000033870A2 (fr) | 2000-06-15 |
| HUP0104857A2 (hu) | 2002-04-29 |
| JP2002531521A (ja) | 2002-09-24 |
| WO2000033870A3 (fr) | 2000-08-17 |
| NZ512005A (en) | 2004-01-30 |
| MXPA01005815A (es) | 2003-04-02 |
| ZA200104163B (en) | 2002-02-04 |
| IL143295A (en) | 2006-04-10 |
| AU777969B2 (en) | 2004-11-04 |
| CZ20012033A3 (cs) | 2001-10-17 |
| US6699483B1 (en) | 2004-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326035B1 (no) | Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse. | |
| US8034360B2 (en) | Use of human prostate cell lines in cancer treatment | |
| Palucka et al. | Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity | |
| US8545835B2 (en) | Human prostate cell lines in cancer treatment | |
| WO2000033871A2 (fr) | Nouveaux traitements du cancer | |
| NZ527763A (en) | Allogeneic immunotherapeutic agent comprising three human prostate tumour cell lines derived from three different primary tumours useful in treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |